4 completed, 4 not yet recruiting, 2 recruiting, 1 enrolling by invitation. 3 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Acute Ischemic Stroke (AIS): new trials by email Literature Review of Acute Ischemic Stroke (AIS) trials Research Report on Acute Ischemic Stroke (AIS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial Tirzepatide, Standard Medical Care (SMC) - Acute Ischemic Stroke (AIS) | Phase 2 / Phase 3 | Not yet recruiting | yifang zhu | 726 | 2026-09-20 | 2026-10-01 |
| Acute Ischemic Stroke Involves Significant Inflammatory Response. This Prospective Cohort Study Evaluates the Predictive Value of Monocyte-, Neutrophil-, and Leukocyte-to-albumin Ratios for Stroke Severity and Functional Outcome Using NIHSS at Admission and Modified Rankin Scale During Follow-up. Acute Ischemic Stroke (AIS) | Not yet recruiting | Sohag University | 60 | 2026-04-01 | 2026-03-17 | |
| Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS). Penumbra System ® - Acute Ischemic Stroke (AIS) | Recruiting | Penumbra Inc. | 200 | 2025-11-01 | 2026-10-20 | |
| Exploration and Establishment of an Early Warning System for Futile Reperfusion - A I S Acute Ischemic Stroke (AIS), Endovascular Thrombectomy | Enrolling by invitation | Xijing Hospital | 2000 | 2025-06-01 | 2025-07-01 | |
| Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents) - Thrombosis, Acute Ischemic Stroke (AIS) | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 390 | 2025-03-01 | 2025-03-06 |
| A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection Single dose, AAPB by injection, intravenous drip., Single dose, placebo, intravenous drip., Multiple dosing, AAPB for injection, intravenous drip - Acute Ischemic Stroke (AIS) | Phase 1 | Not yet recruiting | Jiangsu Kanion Pharmaceutical Co., Ltd | 56 | 2024-11-14 | 2024-11-08 |
| Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke medical management, endovascular thrombectomy - Acute Ischemic Stroke (AIS), Acute Ischemic Stroke From Large Vessel Occlusion | Recruiting | Zhongming Qiu | 1000 | 2024-01-20 | 2025-12-31 | |
| Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg) - Acute Ischemic Stroke (AIS) | Phase 2 | Completed | Silver Creek Pharmaceuticals | 120 | 2022-10-19 | 2026-02-24 |
| Oral Care Strategies for Stroke Patients with Dysphagia oral care, Neuromuscular Electrical Stimulation (NMES) - Acute Ischemic Stroke (AIS), Stroke-Associated Pneumonia (SAP) | Not applicable | Completed | Taipei Medical University Shuang Ho Hospital | 35 | 2021-12-09 | 2024-11-18 |
| Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals Viz.AI software - Acute Ischemic Stroke (AIS) | Not applicable | Completed | The University of Texas Health Science Center, Houston | 443 | 2021-01-01 | 2023-06-28 |
| Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke MCI-186, Placebo - Acute Ischemic Stroke (AIS) | Phase 2 | Completed | Shionogi | 36 | 2009-02-28 | 2026-07-16 |
Ischemic Stroke (11) · Deglutition Disorders (1) · Stroke (1) · Thrombosis (1)
Brain Diseases (11) · Cardiovascular Diseases (11) · Central Nervous System Diseases (11) · Cerebrovascular Disorders (11) · Nervous System Diseases (11) · Vascular Diseases (11) · Stroke (10) · Digestive System Diseases (1) · Embolism and Thrombosis (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Otorhinolaryngologic Diseases (1) · Pharyngeal Diseases (1)
Dental Care Team (1) · Edaravone (1) · Infusions, Intravenous (1) · Injections (1) · Practice Management, Medical (1) · Tirzepatide (1) · Tissue Plasminogen Activator (1)
Jiangsu Kanion Pharmaceutical Co., Ltd (1) · Penumbra Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shionogi (1) · Silver Creek Pharmaceuticals (1) · Sohag University (1) · Taipei Medical University Shuang Ho Hospital (1) · The University of Texas Health Science Center, Houston (1) · Xijing Hospital (1) · Zhongming Qiu (1) · yifang zhu (1)
China (5) · United States (2) · Australia (1) · Canada (1) · Finland (1) · France (1) · Germany (1) · Netherlands (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Guangxiong Yuan (1) · Guodong Xiao, MD.PhD (1) · Marios Nikos Psychogios, Prof MD (1) · Sunil Sheth, MD (1)
PMID 20075087, PMID 24135530, PMID 25671797, PMID 26898852, PMID 27296974, PMID 28052979, PMID 28989804, PMID 29129157, PMID 29364767, PMID 29402504, PMID 30878104, PMID 31662037, PMID 31831388, PMID 34170647, PMID 34647404, PMID 35259929, PMID 36372278, PMID 36596867, PMID 37721738, PMID 37952131, PMID 39536238, PMID 39999799, PMID 40702450, PMID 40886075, PMID 41392086, PMID 41500725
UL1TR003167 (1)